Financial Performance - Q1 2025 revenue increased by 19% year-over-year to $164.2 million, up from $138.5 million in Q1 2024[3] - Q1 2025 net income rose significantly to $12.2 million, compared to a net loss of $4.2 million in Q1 2024[5] - Adjusted gross profit for Q1 2025 increased by 92% to $33.1 million, with an adjusted gross profit margin of 20.2%, up from 12.5% in Q1 2024[6] - Adjusted EBITDA for Q1 2025 surged by 315% to $20.3 million, compared to $4.9 million in Q1 2024[7] - Revenue increased to $164,226,000 in Q1 2025, up 18.5% from $138,539,000 in Q1 2024[33] - Adjusted EBITDA for Q1 2025 was $20,293,000, representing an Adjusted EBITDA margin of 12.4%, compared to $4,885,000 and 3.5% in Q1 2024[31] - Adjusted Gross Profit for Q1 2025 was $33,135,000, with an Adjusted Gross Profit margin of 20.2%, up from $17,252,000 and 12.5% in Q1 2024[33] - The company reported a gross profit of $31,244,000 for Q1 2025, compared to $14,371,000 in Q1 2024[33] Cash Flow and Operations - Cash from operations in Q1 2025 was $16.3 million, significantly up from $1.3 million in Q1 2024[9] - As of March 31, 2025, cash, cash equivalents, and cryptocurrencies totaled $43.3 million, an increase from $31.0 million at the end of 2024[8] - Cash and cash equivalents at the end of Q1 2025 were $34,962,000, down from $42,151,000 at the end of Q1 2024[25] - The company acquired $7,824,000 in Bitcoin for investment during Q1 2025[25] Expenses and Liabilities - Total operating expenses decreased by 7% to $15.3 million in Q1 2025, down from $16.6 million in Q1 2024[4] - Total current liabilities increased to $41,932,000 as of March 31, 2025, compared to $40,629,000 at the end of 2024[23] - Total liabilities decreased slightly to $94,311,000 as of March 31, 2025, from $96,590,000 at the end of 2024[23] - The accumulated deficit decreased to $39,304,000 as of March 31, 2025, from $44,349,000 at the end of 2024[23] Market Position and Future Outlook - The company operates over 8,400 kiosk locations across 48 states, maintaining the largest market share in North America[13] - The company expects revenue growth in Q2 2025 to be in the low-to-mid-single digits percentage range compared to Q2 2024[10] - Bitcoin Depot increased its bitcoin holdings by acquiring 83 more BTC in Q1 2025, bringing the total to 94.35 BTC[8]

Financial Performance - The net loss for Q1 2025 was $7.7 million, significantly lower than the $17.3 million loss in Q1 2024, attributed to changes in the fair value of warrants[11]. - The net loss for the three months ended March 31, 2025, was $7,659 million, a decrease from a net loss of $17,327 million in the same period of 2024, reflecting an improvement of 55.7%[24]. - Basic and diluted loss per share of Common Stock decreased to $0.33 for the three months ended March 31, 2025, compared to $2.78 for the same period in 2024, showing a significant reduction in loss per share[24]. - The company reported a loss before tax of $7,658 million for the three months ended March 31, 2025, down from $17,322 million in the same period of 2024, reflecting a decrease of 55.7%[24]. - Operating loss for the three months ended March 31, 2025, was $7,756 million, compared to $6,785 million for the same period in 2024, indicating an increase of 14.3%[24]. Research and Development - Research and development expenses for Q1 2025 were $5.3 million, an increase from $4.1 million in Q1 2024, driven by preparations for the Phase 2b trial of BX004 and increased expenses for the BX211 trial[9]. - Research and development expenses for the three months ended March 31, 2025, were $5,250 million, up from $4,105 million in the same period of 2024, indicating an increase of 27.8%[24]. - BiomX announced positive topline results from the Phase 2 trial of BX211, showing a statistically significant reduction in ulcer size with a p-value of 0.046 at week 12[6]. - BX211 demonstrated a greater than 40% reduction in ulcer size compared to placebo by week 10, with significant improvements in ulcer depth and area expansion[14]. - The company is planning a Phase 2/3 clinical trial for BX211 pending feedback from the FDA[6]. - The company anticipates the Phase 2b readout of BX004 for cystic fibrosis in Q1 2026, supported by recent financing activities[7]. Financial Position - BiomX reported a cash balance of $21.2 million as of March 31, 2025, up from $18.0 million at the end of 2024, primarily due to financing activities[8]. - BiomX's cash resources are estimated to be sufficient to fund operations into Q1 2026[8]. - As of March 31, 2025, total current assets increased to $23,533 million from $20,520 million as of December 31, 2024, representing a growth of 14.6%[20]. - Total stockholders' equity increased to $24,499 million as of March 31, 2025, from $24,148 million as of December 31, 2024, marking a rise of 1.5%[20]. - Total current liabilities decreased to $7,021 million as of March 31, 2025, from $8,267 million as of December 31, 2024, a reduction of 15.1%[20]. - Non-current liabilities rose to $14,134 million as of March 31, 2025, from $10,818 million as of December 31, 2024, an increase of 30.5%[20]. Shareholder Information - The weighted average number of shares used in computing basic and diluted loss per share increased significantly to 23,103,105 for the three months ended March 31, 2025, compared to 6,229,228 for the same period in 2024[24].

Revenue Performance - Revenues for the three months ended March 31, 2025, were $21,677,564, a decrease of 4.6% compared to $22,723,591 for the same period in 2024[21] - Total revenue for the three months ended March 31, 2025, was $21,677,564, a decrease of approximately 4.6% compared to $22,723,591 for the same period in 2024[87] - Revenue decreased from approximately $22.72 million for the three months ended March 31, 2024 to $21.68 million for the three months ended March 31, 2025, primarily due to a decrease of approximately $0.84 million in sales volume of transmission products[188] Profitability - Gross profit increased to $6,660,950, representing a gross margin of 30.7%, compared to $5,647,069 and a margin of 24.9% in the prior year[21] - Net income attributable to Greenland Technologies Holding Corporation was $4,003,783, up 60.0% from $2,502,203 in the same quarter of 2024[21] - Net income for the three months ended March 31, 2025, was $4,562,836, an increase of 28% compared to $3,569,248 for the same period in 2024[27] - The company reported a total comprehensive income of $4,415,919 for the three months ended March 31, 2025, compared to $1,848,395 in the prior year[21] Expenses and Cost Management - Research and development expenses significantly decreased to $81,457 from $987,724 in the same quarter of 2024, reflecting a strategic focus on cost management[21] - Operating expenses totaled approximately $1.85 million, a significant decrease of $1.87 million or 50.2% from $3.72 million in the prior year[199] - Selling expenses were approximately $0.33 million, a decrease of $0.22 million or 39.6% from $0.55 million in the prior year, mainly due to reduced shipping and marketing costs[200] - General and administrative expenses decreased to approximately $1.44 million, down by $0.74 million or 34.1% from $2.18 million in the previous year[201] - Interest expenses were nil for the three months ended March 31, 2025, a decrease of 100% compared to approximately $0.04 million in the same period last year[205] Assets and Liabilities - Total current assets increased to $93,467,880 as of March 31, 2025, compared to $92,646,759 at the end of 2024[15] - Total liabilities decreased to $60,557,999 from $62,307,307 as of December 31, 2024[18] - Shareholders' equity rose to $58,091,598, an increase from $53,268,888 at the end of 2024[18] - Cash and cash equivalents decreased to $5,403,254 from $6,659,142 at the end of 2024, indicating a need for improved cash flow management[15] - Accounts receivable increased to $21,424,889 as of March 31, 2025, compared to $15,796,423 as of December 31, 2024[131] - Inventories, net, as of March 31, 2025, were $23,944,050, slightly up from $23,378,090 as of December 31, 2024[133] - Property, plant, and equipment, net, decreased to $12,752,390 as of March 31, 2025, from $13,134,648 as of December 31, 2024[137] Cash Flow - Total cash provided by operating activities was $1,244,666, a significant improvement from a cash used of $(8,422,330) in the prior year[27] - The company reported a net decrease in cash and cash equivalents of $(1,222,914) for the quarter, compared to $(7,962,895) in Q1 2024[30] - Cash and cash equivalents at the end of the period were $7,546,848, down from $19,835,290 at the end of Q1 2024[30] Sales and Market Performance - The company sold 38,734 sets of transmission products in Q1 2025, a decrease of 7% from 41,866 sets sold in Q1 2024[35] - Domestic sales for the three months ended March 31, 2025, were $21,184,973, down from $22,524,060 in 2024, a decrease of about 5.9%[167] - International sales increased significantly to $492,591 for the three months ended March 31, 2025, compared to $199,531 in 2024, representing an increase of approximately 146.5%[167] Strategic Initiatives - HEVI Corp. launched the H55L and H65L all-electric wheeled front-end loaders in August 2024, expanding its electric industrial vehicle product line[36] - The company formed a partnership with Lonking Holdings Limited in July 2024 to develop and distribute heavy electric machinery for the U.S. market[36] Financial Reporting and Compliance - The company adopted ASU No. 2016-13 for credit losses on January 1, 2023, enhancing its financial reporting on receivables[65] - The company adopted ASU 2023-07 on January 1, 2024, which did not have a material impact on financial disclosures[119] - The effective tax rate for the three months ended March 31, 2025 was 16.14%, lower than the PRC tax rate of 25.0% due to the China Super R&D deduction[169] Other Financial Metrics - The allowance for expected credit losses is based on customer risk characteristics, past collection experience, and current economic conditions, reflecting a proactive approach to managing receivables[66] - The company does not have a liability for unrecognized tax benefits as of March 31, 2025, indicating a stable tax position[96] - Total government subsidies recorded in other long-term liabilities were $1.21 million as of March 31, 2025, slightly down from $1.26 million as of December 31, 2024[93]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41898 IRON HORSE ACQUISITIONS CORP. (Exact name of registrant as specified in its charter) | Delaware | 87-4105289 | | --- | --- | ...

IPO Details - The company completed its IPO on December 29, 2023, raising gross proceeds of $69,000,000 from the sale of 6,900,000 Units at $10.00 per Unit[132]. - The company incurred transaction expenses of $4,651,705 related to the IPO, including $586,500 in cash underwriting fees and $2,518,500 in deferred underwriting fees[133]. - The underwriters are entitled to a deferred underwriting discount of 3.65% of the gross proceeds of the IPO, amounting to $2,518,500, payable upon the closing of an initial business combination[152]. Financial Position - As of March 31, 2025, the company had $73,567,534 in cash held in the Trust Account, with $167,650 withdrawn for franchise taxes[145]. - As of March 31, 2025, the company had cash of $88 outside the Trust Account, intended for SEC compliance and due diligence on target businesses[146]. Income and Revenue - For the three months ended March 31, 2025, the company reported a net income of $83,760, with interest income of $752,929 from marketable securities[141]. - The company has not generated any operating revenues to date and does not expect to do so until after completing its initial business combination[140]. Business Combination - A business combination agreement was entered into on September 29, 2024, with the potential issuance of between 40,988,000 and 47,888,000 shares of Common Stock to the seller[136]. - The company may need to raise additional funds to meet operating expenditures and complete a business combination[147]. - The company faces substantial doubt about its ability to continue as a going concern if a business combination is not completed by June 29, 2025[149].

Revenue and Sales Performance - Revenues increased from $2,293,331 for the three months ended March 31, 2024, to $3,599,099 for the three months ended March 31, 2025, an increase of approximately 56.94%[181] - 5G sales were approximately $75,000, while Spectrum sales increased by $1,361,099, or 108.67%, attributed to a rebound in the Asian markets[181] Profit and Loss - Gross profit increased to $1,187,870 for the three months ended March 31, 2025, compared to $882,630 for the same period in 2024, an increase of 34.58%[182] - The Company reported a net loss of $1,840,521 for the three months ended March 31, 2025, compared to a net loss of $4,655,161 for the same period in 2024[188] Research and Development - Research and development costs rose to $739,673 for the three months ended March 31, 2025, from $276,755 in 2024, an increase of 167.27%[185] Financial Agreements and Transactions - The Company entered into an equity distribution agreement to offer and sell shares of common stock with an aggregate offering price of up to $25 million[169] - An asset purchase agreement was signed for the acquisition of assets, including intellectual property, for a total purchase price of $8,000,000[171] - A non-binding letter of intent was established for the purchase of $78 million of the Company's Oran radios, with $810,000 in purchase orders received to date[178] Investment and Financial Position - The Company recorded a complete loss from the investment in digital assets of $3,248,911 due to fraudulent transactions[168] - The outstanding balance on the Revolving Line of Credit was $0 as of March 31, 2025, with a credit limit of up to $750,000 established for general working purposes[174] - As of March 31, 2025, the company had cash and cash equivalents of $16,942,201, a decrease from $19,315,984 as of December 31, 2024[193] - Working capital as of March 31, 2025, was $24,600,230, down from $26,795,745 as of December 31, 2024[193] - The accumulated deficit increased to $22,852,648 as of March 31, 2025, compared to $21,012,127 at the end of 2024[193] - The company believes it can meet its obligations and capital requirements for the next 12 months based on its current cash and cash equivalents and forecasted cash flows[194] Accounting and Regulatory Compliance - There have been no significant changes to critical accounting policies during the three-month period ended March 31, 2025[196] - The company regularly assesses the impact of changes in laws and regulations on its operations[197] - No off-balance sheet transactions were reported[198] - Smaller reporting companies are not required to provide detailed market risk disclosures[199]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-42497 ODYSIGHT.AI INC. (Exact name of registrant as specified in its charter) Nevada 47-4257143 (State or other jurisdiction of incorp ...

"We started 2025 with strong momentum and a focus on generating impactful clinical data across our in vivo gene editing pipeline. Early this year, data from the OTC-HOPE trial provided the first clinical validation for ARCUS in vivo gene insertion following a complete response in an infant with OTC-deficiency," said Michael Amoroso, Chief Executive Officer of Precision BioSciences. "In addition, the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV, our lead program for chronic Hepatitis B, is progressing as ...

Exhibit 99.1 Net income for the first quarter of 2025 was $2.0 million compared to $2.2 million during the quarter ended March 31, 2024. Basic earnings per share and diluted earnings per share were $0.22 and $0.20, respectively, compared to $0.23 and $0.21 for the first quarter of 2024. Excluding the impact of elevated merger- and acquisition-related expense for the first quarter of 2025, net income and earnings per share would have been comparable or higher than during the first quarter of 2024. Adjusted E ...

Financial Performance - Earnings per share increased by 30% year-over-year, reaching $0.10 compared to $0.08 in the prior year[2] - Revenue for Q1 2025 was $8.2 million, a decrease of 13% from $9.4 million in Q1 2024, primarily due to a new product sell-in that did not repeat[4] - Gross margin improved to 75.4% in Q1 2025 from 72.0% in Q1 2024, driven by a favorable product mix[6] - Net income rose by 51% to $876.3 thousand in Q1 2025, up from $580.5 thousand in Q1 2024[7] - EBITDA for Q1 2025 was $1.98 million, a 7% increase from $1.85 million in Q1 2024, attributed to lower SG&A expenses[8] - Operating expenses decreased by 15% to $4.2 million in Q1 2025 from $5.0 million in Q1 2024[6] International Expansion - The company is preparing for international expansion into three new markets later in 2025 for its FOCUSfactor brand and Ready-To-Drink beverages[2] - Synergy established a wholly owned subsidiary in Mexico and is onboarding key suppliers and retailers in the region[5] Debt and Cash Flow Management - The company aims to refinance its debt to extend the maturity date to 2029, which is expected to enhance free cash flow[2] - Total liabilities decreased by $1.7 million to $31.3 million as of March 31, 2025, compared to $33.0 million at the end of 2024[9] - Net cash used in operating activities was $(822,781) for the three months ended March 31, 2025, slightly improved from $(858,042) in the same period of 2024[22] - Cash and restricted cash at the end of the period was $277,882, down from $1,010,749 at the end of the same period in 2024, indicating a decrease of 72.5%[22] - Net cash provided by financing activities was $314,678 for the three months ended March 31, 2025, compared to $1,004,620 in the same period of 2024, a decline of 68.7%[22] - Cash paid for interest during the period was $573,529, down from $1,102,781 in the same period of 2024, a decrease of 47.9%[22] - Advances from related party amounted to $135,000, a significant decrease from $1,400,000 in the same period of 2024[22] Asset Management - Accounts receivable increased by $940,519, while inventory decreased by $(629,935) during the three months ended March 31, 2025[22] - The company issued common stock for loan financing amounting to $117,648 during the period[22] Foreign Currency Impact - The company reported a foreign currency transaction loss of $(3,137) for the three months ended March 31, 2025, compared to a gain of $11,178 in the same period of 2024[22] - The effect of exchange rate on cash, cash equivalents, and restricted cash resulted in a loss of $(1,935) for the three months ended March 31, 2025[22]